Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026

Pulsenmore advanced U.S. commercialization after FDA marketing authorization and reported 6M26 revenues of NIS 6.1m (~$2.0m), up 53% YoY (from NIS 4.0m). However, losses remain large: operating loss was NIS 20.8m (~$7.0m) and net/comprehensive loss rose to NIS 35.0m (~$11.8m) in 6M26, partly due to higher net financial expenses tied to the private placement. The company also raised about NIS 22.5m (~$7.5m) gross via a healthcare-focused institutional private placement and ended 6/30/26 with NIS 70m (~$23.4m) in cash and deposits.

Analysis

The market should treat this as a proof-of-concept stage, not a scale story. The key issue is conversion risk: the company has regulatory permission and pilot logos, but the equity still hinges on whether U.S. provider onboarding turns into repeatable utilization rather than one-off installs. In the next 1-3 months, the webcast matters only if management quantifies monthly orders, churn, reimbursement progress, and gross margin per device; otherwise the news flow is mostly narrative.

The hidden overhang is dilution and financing optics. The warrant structure and reported warrant liability create a ceiling on valuation until the market sees operating leverage; with losses still roughly flat at the operating line, any commercialization spend uptick will likely be funded before it is self-financing. Competitively, the winners from remote maternal monitoring may be telehealth platforms and provider networks that can bundle the device into care pathways; the losers, if adoption proves real, are traditional imaging workflows and portable ultrasound incumbents, but that is a 6-18 month question, not a near-term trade.

The contrarian bull case is that investors are underestimating how quickly a regulated, niche workflow can scale once a major payer/provider stack blesses it. The contrarian bear case is stronger: grants and partnerships are not demand, and the first meaningful falsifier is any quarter where U.S. revenue remains immaterial while commercial opex steps up. If 2H bookings do not inflect meaningfully versus H1, the stock likely reverts to a financing and execution discount.

Key Decisions for Investors

• Do not chase PLSM into the webcast; wait 24-48 hours for quantified U.S. revenue run-rate, provider utilization, and reimbursement commentary. If management gives only qualitative language, treat the announcement as non-investable narrative.
• Speculative short PLSM on strength into the next 1-2 sessions, with a stop if they disclose a material step-up in U.S. recurring orders or a system-wide payer rollout. The risk/reward is favorable because dilution and execution risk are still ahead of revenue scalability.
• If liquidity allows, run a relative-value short PLSM / long BFLY basket over the next 1-3 months to express 'pre-scale narrative vs. operating scale' divergence. Cover the short if PLSM shows two consecutive quarters of accelerating U.S. bookings and improving gross margin.
• Set an alert on any quarter where U.S. revenue exceeds H1 by at least 50% and cash burn does not accelerate proportionally. That combination would falsify the 'story stock' thesis and force a reassessment of upside.